Icotrokinra, approved in March 2026, is a 13-amino-acid cyclic peptide taken as a daily tablet that beat both placebo and an oral small molecule in Phase 3. It works with an oral bioavailability of a few tenths of one percent and no absorption enhancer.
A September 2026 Nature Communications study reports that trifluoroacetate, the counterion on most synthetic peptides, binds PPAR-alpha and produces metabolic effects in mice, including when it arrives attached to unrelated peptides. What that means for experimental design.
GLP-1 demand pushed peptide synthesis to metric-ton scale. At the same moment the EU restricted DMF and added DMAc and NEP to Annex XVII. The chemistry that makes peptides runs on solvents Europe is phasing out.
In one month: computationally designed antimicrobial nanopores that work in mice, an engineered peptide nanopore that detects single α-synuclein species, and LLM-assisted design of cell-penetrating peptides. The three are not the same kind of result.
Novo Nordisk ran one peptide two ways in the same trial network. The top oral arm received about nine times more drug per week than the injected arm — for a smaller effect. A rare direct measurement of the oral peptide tax.
Human amylin forms amyloid fibrils in the pancreas, which is why it was undruggable. Three proline substitutions borrowed from rat amylin fixed it. And its receptor is not a receptor at all.
Search for the two-peptide blend of GHK-Cu and KPV and you will not find one product. You will find at least eight different names for what is, in most cases, the same vial — and two different formulations sold under those names without anyone flagging the difference. This is a nomenclature problem, not a chemistry…
A term has been circulating in grey-market listings: GLP-4, presented as the successor to the incretin peptides that came before it. Before assessing any such claim, a laboratory needs a prior question answered — does the molecule exist in the published record at all? We searched PubMed and the clinical trial registries on 2 August…
A name arrives before the data does. Omegatide appears in vendor listings and forum threads as though it were a compound with a history, and readers reasonably assume that a name of that shape — the -tide ending, the single word — points to a single characterised molecule. It does not. Searching PubMed on 2…
“Metatrutide” circulates in grey-market peptide catalogues and forum threads as though it were an established compound with a defined structure. It is not. Searching the primary literature for the name returns nothing at all, while the compound it is usually associated with — retatrutide — has a substantial and traceable publication record. That asymmetry is…
Cookies
We use strictly necessary cookies to run the store. With your consent we also use analytics (order attribution) and marketing (Omnisend) cookies. Read our Cookie Policy.
